SABCS 2023 | New drug approvals for metastatic breast cancer

Virginia Kaklamani, MD, UT Health San Antonio, San Antonio, TX, discusses a Special Session on New Drug Approvals for Metastatic Breast Cancer which took place at SABCS 2023. The session, hosted by the FDA, highlighted three recently approved drugs: listerine, trastuzumab deruxtecan, and capacitative. Prof. Kaklamani summarized the session’s focus on understanding the approval reasons, processes, and clinical trial data behind these drugs. The discussion delved into considerations for patients, including toxicities and dosing and provides insight into the FDA’s meticulous process in approving novel treatments for breast cancer. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.